Capricor Therapeutics says the United States Food and Drug Administration (FDA) is willing to review an amendment containing 24-month HOPE-3 data for deramiocel, keeping the experimental Duchenne muscular dystrophy cell therapy under active consideration despite a strongly negative advisory committee vote. The company intends to narrow the regulatory case from Duchenne-associated cardiomyopathy to preservation of upper limb skeletal muscle function, the area in which Capricor believes the Phase 3 evidence is most persuasive. Once the amendment is submitted, the FDA is expected to extend the existing August 22, 2026, target action date, although neither the length of the extension nor the classification of the amendment has been confirmed.
The development gives Capricor another opportunity to strengthen the application, but it should not be interpreted as a signal that approval is likely. FDA reviewers previously concluded that the prespecified HOPE-3 analysis did not establish a statistically significant upper limb benefit and that the evidence for cardiac effectiveness was inconclusive. An independent advisory committee subsequently voted nine to three that the available evidence did not demonstrate deramiocel’s effectiveness for Duchenne cardiomyopathy.
The planned amendment will add longer-term open-label extension data and analyses focused on distal upper limb function. Those results could help the FDA evaluate whether any functional effect becomes more convincing or durable over 24 months. However, an open-label extension cannot recreate the protection against bias provided by the original randomized, placebo-controlled period. The central regulatory question is therefore not simply whether patients receiving deramiocel showed improvement relative to their previous trajectory, but whether the total evidence can overcome the statistical and interpretive problems already identified by FDA reviewers.
What changed in the FDA review of Capricor’s deramiocel?
Capricor disclosed during its second-quarter update that it plans to amend the deramiocel Biologics License Application with 24-month data from the HOPE-3 open-label extension and additional analyses from the existing clinical package. The company said the FDA had indicated that it was willing to review the amendment and extend the current action date after receiving it.
Parent Project Muscular Dystrophy subsequently said Capricor had confirmed that the amendment would narrow the proposed indication to upper limb dysfunction. The patient advocacy organization also cautioned that submission of additional information does not indicate how the FDA will ultimately decide the application.
The regulatory timeline remains uncertain. Capricor has not said whether the FDA will classify the submission as a major amendment. A major amendment commonly provides the agency with additional review time, but the exact extension cannot be assumed until the FDA formally accepts and classifies the filing.
The agency could ultimately approve deramiocel for a narrowed population, request another controlled study, issue a further complete response letter or determine that the revised evidence still does not meet the substantial-evidence standard. Agreement to receive data keeps those possibilities open. It does not resolve which outcome is most likely.
Why is Capricor moving away from a cardiomyopathy-focused indication?
Capricor’s original regulatory strategy sought approval for deramiocel to treat cardiomyopathy associated with Duchenne muscular dystrophy. Cardiomyopathy is a major source of illness and mortality in Duchenne because the absence of functional dystrophin damages cardiac muscle as well as skeletal and respiratory muscles.
The clinical need is substantial. Existing Duchenne treatments have not been systematically established as therapies that slow cardiac deterioration, and no product is specifically approved on evidence of preserving cardiac function in Duchenne-associated cardiomyopathy.
The problem for deramiocel is that FDA reviewers did not believe HOPE-3 convincingly demonstrated such an effect. Many participants entered the trial with average left ventricular ejection fractions in the normal range, raising questions about whether the study had enrolled a population with sufficiently established cardiomyopathy to support the requested indication.
The agency also objected to changes in how cardiac results were analysed. The original statistical plan called for assessment of the absolute change in left ventricular ejection fraction. Later versions used ranked changes and other analytical modifications that produced different levels of statistical significance.
Capricor reported that a corrected analysis yielded a 1.8-percentage-point treatment difference in left ventricular ejection fraction with a p-value of 0.09, compared with an earlier topline result of 2.4 percentage points and a p-value of 0.04. The company said the prespecified cardiomyopathy subgroup remained nominally significant, but the FDA considered the broader cardiac evidence small, variable and difficult to interpret.
The advisory committee was asked whether the available evidence established effectiveness for cardiomyopathy. Nine members voted against and three supported the therapy. Although the vote is not binding, it demonstrated that the cardiac argument had failed to persuade most of the outside specialists reviewing the application.
Moving to upper limb function is therefore a logical strategic response. It aligns the proposed use with the functional domain that HOPE-3 was originally designed to evaluate and with the area that received a comparatively more receptive discussion during the advisory meeting.
What did the HOPE-3 Phase 3 study actually show?
HOPE-3 randomized 106 participants with Duchenne muscular dystrophy, with 54 assigned to deramiocel and 52 to placebo. Participants received intravenous infusions once every three months during the 12-month double-blind period. Most received four scheduled doses.
The primary assessment used Performance of the Upper Limb version 2.0, commonly known as PUL 2.0. This validated scale measures tasks involving the shoulders, elbows, wrists and hands. Preserving these functions can be especially meaningful for non-ambulatory patients because upper limb ability affects eating, personal care, wheelchair operation and use of communication devices.
Capricor’s published analysis reported that the deramiocel group experienced a mean percentage decline of 3.86%, compared with an 8.41% decline in the placebo group. The calculated difference was 4.55 percentage points, with a p-value of 0.029. Capricor has described that outcome as achievement of the HOPE-3 primary endpoint.
FDA reviewers reached a different conclusion when they applied the original prespecified analysis of absolute PUL 2.0 score changes. Under that analysis, the least-squares mean decline at 12 months was 1.73 points for deramiocel and 2.39 points for placebo. The between-group difference was 0.66 points, with a 95% confidence interval ranging from a 0.45-point disadvantage to a 1.77-point benefit. The p-value was 0.24.
The agency therefore concluded that the prespecified primary endpoint was not statistically significant. FDA reviewers also questioned whether a 2% to 4% relative change in PUL 2.0 has an established clinical meaning, noting that the instrument is normally interpreted using absolute point changes.
This disagreement is not a minor difference in presentation. It goes to the heart of whether HOPE-3 should be viewed as a successful Phase 3 study or as a trial that generated an encouraging but unconfirmed functional signal.
Why did the FDA object to Capricor’s statistical analysis?
FDA reviewers focused on changes to the statistical analysis plan after the clinical study had been completed. The original plan specified analysis of the absolute change in PUL 2.0 score. Later versions shifted to percentage change and altered the handling of missing data, prohibited medication use and certain patient characteristics.
The company’s reported p-value of 0.029 depended on the later percentage-based model and its assumptions. When FDA reviewers retained elements of the modified model but applied different missing-data handling, the estimated difference fell to 2.53 percentage points and the p-value increased to 0.21.
Only a small number of participants had incomplete or excluded data, but that was precisely why the FDA considered the sensitivity concerning. A result that moves from statistically significant to clearly non-significant when assumptions involving a few patients are changed may not be sufficiently robust to support approval.
The agency also questioned inclusion of a slow-progressor variable that, according to the FDA, should have been removed under the company’s stated criteria because only one treated participant met the relevant classification. Reviewers found that including the variable lowered the p-value.
Capricor has maintained that its published analysis appropriately reflects the clinical effect and that the full results underwent independent peer review before publication in The Lancet. Peer-reviewed publication adds scientific visibility and allows outside researchers to examine the methodology, but it does not require the FDA to accept an analysis that differs from the agency’s understanding of the trial’s prespecified plan.
For a pivotal study, the timing of analytical decisions is crucial. Prespecification prevents researchers from testing multiple methods after seeing the shape of the data and selecting the one that produces the most favourable outcome. Even when investigators remain formally blinded, changes made after data collection can introduce concerns about bias, particularly when adverse-event patterns may have allowed participants or staff to infer treatment assignment.
Can the 24-month HOPE-3 data resolve the efficacy dispute?
Longer follow-up could provide valuable information about whether upper limb trajectories continue to separate. Duchenne muscular dystrophy is progressive, and a treatment that slows functional loss may produce a more visible difference over two years than over one.
The 24-month data may also show whether a modest short-term difference becomes sustained, increases with repeated dosing or disappears. Analyses focused on distal function could be relevant because hand and wrist abilities may remain measurable after shoulder function has substantially declined.
However, the open-label extension has an unavoidable limitation. After completing the randomized period, participants could receive deramiocel without remaining in their original blinded treatment groups. Once both former placebo and active-treatment patients are receiving the therapy, the study no longer provides a concurrent untreated control for the full 24 months.
Investigators can compare participants with their previous results, their original randomization groups or external natural-history datasets. Each approach may be informative, but none has the same evidentiary strength as a prospectively designed, randomized comparison.
Disease progression in Duchenne is also heterogeneous. Age, ambulatory status, baseline PUL score, corticosteroid treatment, genotype and disease stage can influence the rate of decline. External comparisons therefore require careful matching and sensitivity analyses.
The 24-month amendment is most likely to help if it demonstrates a consistent pattern across several measures, retains a plausible magnitude of benefit and does not rely on a narrow set of statistical assumptions. It is less likely to resolve the dispute if the apparent effect changes substantially across analytical methods or depends primarily on post hoc subgroup selection.
Does deramiocel have a manageable safety profile?
Deramiocel consists of allogeneic cardiosphere-derived cells obtained from donor heart tissue. Capricor proposes that the cells release exosomes and growth factors with anti-inflammatory, antifibrotic and immunomodulatory effects rather than permanently replacing damaged muscle.
Of the 106 randomized HOPE-3 participants, 105 received study treatment and were included in the safety analysis. One hundred and three participants received more than one infusion, while most completed the four-dose schedule.
Six serious adverse events occurred during the randomized period. Five were reported among placebo recipients and one occurred in a deramiocel-treated participant. The treatment-related serious event in the deramiocel group was a Grade 2 infusion reaction that required temporary interruption, allergy medication and intravenous fluids. The participant later continued treatment.
A life-threatening anaphylactic reaction occurred in a placebo participant. FDA reviewers considered it potentially related to the excipients because the placebo contained the formulation components without the cardiosphere-derived cells.
Hypersensitivity reactions were more frequent with active treatment, occurring in 41.5% of deramiocel recipients compared with 15.4% of placebo participants. These events included fever, rapid heart rate, rash, throat symptoms, flushing and other infusion-related reactions.
Capricor says deramiocel has been administered in approximately 1,300 infusions to more than 200 patients across three trials. More than 80 patients are participating in open-label extension studies, including some treated continuously for more than five years. That exposure provides useful longer-term reassurance, but hypersensitivity remains an important consideration for a therapy administered intravenously every three months.
The benefit-risk judgment ultimately depends on efficacy. A manageable infusion-reaction profile may be acceptable for a treatment that clearly preserves meaningful function in a progressive fatal disease. The same risks become harder to justify if the magnitude and reliability of the benefit remain uncertain.
Could manufacturing or inspection findings create another FDA hurdle?
Capricor has said its San Diego manufacturing facility is operational and capable of supporting an initial commercial launch. FDA reviewers also indicated that deramiocel produced at the company’s Los Angeles and San Diego facilities was considered equivalent for the HOPE-3 analysis.
The FDA conducted a Bioresearch Monitoring inspection during July and issued a Form 483 containing one observation. Capricor has submitted a response and is awaiting further feedback. The company has not presented the observation as an unresolved barrier to approval, but it remains part of the regulatory record.
Cell therapies require particularly careful control of donor material, manufacturing consistency, product identity, potency, sterility, storage and infusion preparation. Approval depends on more than favourable clinical statistics. The FDA must be satisfied that commercial production will reliably deliver a product comparable to the material used in clinical studies.
Capricor is also validating an expansion of its San Diego facility, with inspection of the additional space expected in 2027. That expansion is intended to support future scale rather than the initial launch configuration.
How should the FDA’s willingness to review more data be interpreted?
The most defensible interpretation is that deramiocel has not been ruled out. The FDA could have proceeded toward the existing decision date using the current application, but it is instead prepared to consider more information and allow additional review time.
That is meaningful for Capricor and the Duchenne community. It gives the company an opportunity to present a narrower indication aligned with functional preservation, an area of major importance for patients who have lost or are losing ambulation.
It does not erase the nine-to-three advisory committee vote, the non-significant result under the original statistical plan or the FDA’s concerns about post-study analytical changes. The amendment must address those issues rather than simply add more data around them.
Capricor has slowed commercial spending and placed unrelated pipeline programs on hold while waiting for regulatory clarity. The company reported approximately $237.9 million in cash, cash equivalents and marketable securities at the end of June, which it believes can support operations for at least the next 12 months. That provides some capacity to continue the review or prepare for further clinical work if requested.
The new path is narrower but clinically coherent. Upper limb preservation may be easier to connect directly with daily function than small changes in cardiac imaging, particularly in patients who entered HOPE-3 without clear cardiac dysfunction. Yet the regulatory standard has not become easier merely because the indication is being reframed.
The decisive evidence will be whether the 24-month results show durable functional separation and whether that finding remains persuasive under analyses the FDA considers prespecified, interpretable and resistant to missing-data assumptions. Until the amendment is filed and reviewed, deramiocel remains neither rescued nor rejected. It remains an investigational therapy facing an unusually consequential second examination of the same underlying Phase 3 evidence.
